Pharmaxis Ltd chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.7
Market capitalization 43.38M
Operating cash flow -16.3M
ESG Scores unknown

Company description

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting myelofibrosis and other cancers, and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial data

Financial Statements

Cashflow Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Change To Liabilities 67k -437k -520k
Total Cashflows From Investing Activities -981k -574k -644k -138k
Net Borrowings -1.59M -2.23M -2.31M
Total Cash From Financing Activities 20.83M -2.5M 1.52M 6.66M
Change To Operating Activities -6.02M -329k 5.22M
Issuance Of Stock 24M 4.37M 4.37M
Net Income -20.06M -13.94M -2.97M -1.93M
Change In Cash 51k -16.36M 3.95M -9.78M
Effect Of Exchange Rate
Total Cash From Operating Activities -19.8M -13.28M 3.07M -16.3M
Depreciation 2.77M 3.12M 3.03M 3.24M
Change To Account Receivables 616k -288k 289k
Other Cashflows From Financing Activities -1.58M -270k -541k 6.66M
Change To Netincome 2.46M -1.01M -1.09M -17.6M
Capital Expenditures -576k -259k -332k

Income Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Research Development 8.66M 7.22M 7.22M 7.22M
Income Before Tax -20.06M -13.94M -2.97M -1.93M
Net Income -20.06M -13.94M -2.97M -1.93M
Selling General Administrative 16.63M 15.81M 16.34M 14.84M
Gross Profit 10.48M 4.82M 17.64M 13.03M
Ebit -19.39M -15.88M -3.75M -14.44M
Operating Income -19.39M -15.88M -3.75M -14.44M
Interest Expense -238k -369k -369k
Income Tax Expense
Total Revenue 12.17M 12.62M 23.58M 15.76M
Cost Of Revenue 1.69M 7.8M 5.93M 2.73M
Total Other Income ExpenseNet -669k 1.94M 776k 12.51M
Net Income From Continuing Ops -20.06M -13.94M -2.97M -1.93M
Net Income Applicable To Common Shares -20.06M -13.94M -2.97M -1.93M

Balance Sheet Statement 2019-06-30 2020-06-30 2021-06-30 2022-06-30
Total Liabilities 37.85M 33.98M 30.75M 14.38M
Total Stockholder Equity 14.81M 1.43M 2.85M 10.8M
Other Current Liabilities 3.74M 2.19M 3.54M
Total Assets 52.67M 35.42M 33.59M 25.19M
Common Stock 367.3M 367.3M 371.37M 10.8M
Other Current Assets 144k 162k 223k
Retained Earnings -374.24M -388.19M -391.16M
Treasury Stock 21.76M 22.32M 22.64M
Cash 31.12M 14.76M 18.71M 8.94M
Total Current Liabilities 8.11M 6.83M 7.89M 1.46M
Other Stockholder Equity 21.76M 22.32M 22.64M
Property, Plant, and Equipment 10.26M 8.91M 6.23M 3.21M
Total Current Assets 40.58M 24.49M 25.31M 19.41M
Net Tangible Assets 14.06M 490k 1.73M 10.8M
Net Receivables 7.19M 6.94M 2.74M 8.14M
Accounts Payable 2.2M 1.76M 1.24M 1.46M


Insider Transactions

Here are the insider transactions of stock shares related to Pharmaxis Ltd:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Delaat (William L)D2022-08-04Former53.33k
McComas (Malcolm J)Purchase at price 0.08 per share.D2021-12-23Chairman of the Board1.02M
Phillips (Gary Jonathan)D2021-12-23Chief Executive Officer1.54M
Phillips (Gary Jonathan)Other at price 0.08 per share.D2021-12-23Chief Executive Officer1.64M
Phillips (Gary Jonathan)Other at price 0.08 per share.D2021-12-23Chief Executive Officer1.64M
Phillips (Gary Jonathan)Other at price 0.08 per share.D2021-12-22Chief Executive Officer95.24k
McComas (Malcolm J)Other at price 0.08 per share.D2021-12-22Chairman of the Board285.71k
Jarolimek (Wolfgang G)D2021-06-30Divisional Officer600k
McComas (Malcolm J)Other at price 0.06 per share.D2021-06-25Chairman of the Board217.13k
McComas (Malcolm J)Other at price 0.06 per share.D2021-06-25Chairman of the Board217.13k
McComas (Malcolm J)D2021-05-03Chairman of the Board686.67k
McComas (Malcolm J)Other at price 0.07 per share.D2021-04-30Chairman of the Board200k
McComas (Malcolm J)D2019-06-30Chairman of the Board13.33k
McGarvey (David Morris)D2019-06-30Chief Financial Officer10k
Phillips (Gary Jonathan)D2019-06-30Chief Executive Officer769k
Buckingham (Simon Hugh William)D2018-11-22Retired200k
Buckingham (Simon Hugh William)Other at price 0.24 per share.D2018-09-21Director (Non-Executive)44k
Delaat (William L)Other at price 0.24 per share.D2018-09-21Director (Non-Executive)20k
Hanley (Denis Michael)Other at price 0.24 per share.D2018-09-21Director (Non-Executive)1.19M
McComas (Malcolm J)Other at price 0.24 per share.D2018-09-21Chairman of the Board126.36k
Phillips (Gary Jonathan)D2018-09-21Chief Executive Officer45.15k
Charlton (Brett)D2018-06-30Divisional Officer353.5k
Phillips (Gary Jonathan)D2017-11-13Chief Executive Officer770k
Morgan (Kristen)D2017-06-30Divisional Officer43.48k
McComas (Malcolm J)D2017-06-30Chairman of the Board3.79k
McComas (Malcolm J)Purchase at price 0.20 per share.D2016-12-02Chairman of the Board200k
Phillips (Gary Jonathan)D2016-09-29Chief Executive Officer815k
Phillips (Gary Jonathan)Sale at price 0.21 per share.D2016-09-29Chief Executive Officer400k
McGarvey (David Morris)D2016-06-30Chief Financial Officer280k
Charlton (Brett)D2016-06-30Divisional Officer271.25k
Jarolimek (Wolfgang G)D2016-06-30Divisional Officer265.7k
Phillips (Gary Jonathan)D2015-07-31Chief Executive Officer775k
McGarvey (David Morris)D2015-06-30Chief Financial Officer208k
Velummylum (Geethanjali)D2015-06-30Former2.34k
Charlton (Brett)D2015-06-30Divisional Officer47.75k
Gallac� (Mirella Catherine)D2015-06-30Former2.34k
Jarolimek (Wolfgang G)D2015-06-30Divisional Officer353.85k
Phillips (Gary Jonathan)D2015-05-18Chief Executive Officer1.03M
Charlton (Brett)D2014-06-30Divisional Officer283.17k
Crapper (John Francis)D2014-06-30Divisional Officer2k
Buckingham (Simon Hugh William)Purchase at price 0.12 per share.D2013-10-29Director (Independent)200k
van den Broek (Richard A)I2013-09-19Retired1.13M
Velummylum (Geethanjali)D2013-06-30Divisional Officer2.34k
Charlton (Brett)D2013-06-30Divisional Officer215k
Gallac� (Mirella Catherine)D2013-06-30Divisional Officer2.34k
Jarolimek (Wolfgang G)D2013-06-30Divisional Officer2k
McGarvey (David Morris)D2013-06-30Chief Financial Officer220k
Phillips (Gary Jonathan)D2013-05-02Chief Executive Officer30k
van den Broek (Richard A)Purchase at price 0.34 per share.I2013-03-28Director (Non-Executive)300k
Robertson (Alan Duncan Ph.D.)D2012-06-30Chief Executive Officer100k
Charlton (Brett)D2012-06-30Divisional Officer215k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Pharmaxis Ltd. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Pharmaxis Ltd

Here is the result of two systematic investment strategies applied to Pharmaxis Ltd. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Pharmaxis Ltd

The following chart shows the equity curve of the two systematic investment strategies applied to Pharmaxis Ltd:

Pharmaxis Ltd automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -46.81% on the backtest period.

Performance at glance

Performance

-46.81 %

Latent gain

-1169.88 $

Invested capital

2499.48 $

Annualized return

-11.25 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Pharmaxis Ltd

This is the result of two momentum investment strategies applied to Pharmaxis Ltd. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Pharmaxis Ltd

The following chart shows all the entries opened by the momentum investment system on Pharmaxis Ltd:

Pharmaxis Ltd momentum entries
  • The first momentum investment strategy would give -46.85% of return on Pharmaxis Ltd. That represents -2342.51$ of latent gain with 4999.84$ of employed capital.
  • The second momentum investment strategy would give -45.31% of return on Pharmaxis Ltd. That represents -1925.57$ of latent gain with 4249.65$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-46.85 %

Latent gain

-2342.51 $

Invested capital

4999.84 $

Annualized return

-29.8 %
Performance at glance (2Q Momentum)

Performance

-45.31 %

Latent gain

-1925.57 $

Invested capital

4249.65 $

Annualized return

-12.31 %

Momentum equity curve on Pharmaxis Ltd

The following chart shows the equity curve of the two momentum strategies applied to Pharmaxis Ltd:

Pharmaxis Ltd momentum equity

Note: the dividends potentially given by Pharmaxis Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pharmaxis Ltd

The following chart shows the employed capital evolution of the two momentum strategies on Pharmaxis Ltd since the beginning:

Pharmaxis Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Pharmaxis Ltd

Buy the dip entry openings on Pharmaxis Ltd

Pharmaxis Ltd

The performance achieved by the robo-advisor on Pharmaxis Ltd is -64.36%. That represents -482.72$ of latent gain with 750.07$ of employed capital. The following chart shows Pharmaxis Ltd stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Pharmaxis Ltd, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-64.36 %

Latent gain

-482.72 $

Invested capital

750.07 $

Annualized return

-29.8 %

Equity curve of the strategy applied to Pharmaxis Ltd

The following chart shows the result of the investment strategy applied to Pharmaxis Ltd:

Pharmaxis Ltd

Note: the dividends potentially given by Pharmaxis Ltd are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Pharmaxis Ltd

The following chart shows the employed capital evolution since the beginning of the investment strategy on Pharmaxis Ltd:

Pharmaxis Ltd

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Pharmaxis Ltd

In this section, I will compare the three previous investment strategies applied to Pharmaxis Ltd.

Equity curve comparison on Pharmaxis Ltd

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Pharmaxis Ltd investment strategy comparison

Employed capital comparison on Pharmaxis Ltd

Pharmaxis Ltd investment comparison

Performance comparison on Pharmaxis Ltd

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -46.81% -1169.88$ 2499.48$ -11.25%
Momentum 1 quarter -46.85% -2342.51$ 4999.84$ -11.95%
Momentum 2 quarters -45.31% -1925.57$ 4249.65$ -12.31%
Non-directional -64.36% -482.72$ 750.07$ -29.8%
Annualized return comparison

Automatic investment

-11.25 %

Momentum 1Q

-12.31 %

Momentum 2Q

-12.31 %

Non-directional

-29.8 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Pharmaxis Ltd:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Pharmaxis Ltd and the other stocks. There may be false positives or some missing correlated stocks. If the price of Pharmaxis Ltd does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Pharmaxis Ltd
Country Australia
City Frenchs Forest
Address 20 Rodborough Road
Phone 61 2 9454 7200
Website www.pharmaxis.com.au
FullTime employees
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XASX
Ticker PXS.XASX
Market www2.asx.com.au

Pharmaxis Ltd ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown